Nouvelle déclaration d'incident
No de la demande: 2020-2257
Numéro de référence du titulaire d'homologation: 2019-CA-000019
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Seacaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: ONTARIO
ARLA No d'homologation 29930 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard One Spot Flea and Tick Drops Spot-on
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Homme
0.9
Inconnu
Cutanée
Unknown / Inconnu
<=30 min / <=30 min
Système
Persisted until death
Oui
Non
Euthanised / Euthanasie
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 16-May-2019 a pet owner reported that they applied 1 tube of Hartz UltraGuard OneSpot Flea and Tick Cat Drops (S Methoprene) to the cat on approximately 20-Jan-2019. Immediately after application the cat developed hypersalivation and agitation. The pet owner attempted to wash off the application site with an unknown soap and water. On approximately 21-Jan-2019 the cat developed lethargy. On approximately 27-Jan-2019 the cat developed seizures which continued for three weeks though the frequency of the seizures during that time period was not specified. On approximately 17-Feb-2019 the cat developed muscle weakness in its rear limbs. On 17-Feb-2019 the cat was evaluated by a veterinarian. No diagnostics were performed. The pet owner elected to have the cat humanely euthanized. No necropsy was performed. No further information was received in this case and more information is not expected.
Modérée
Assessment: This product has a wide margin of safety in cats following dermal application. Even if ingested, only minor oral irritation or GI upset would be expected. Delayed onset seizures and muscle weakness are not expected. Other causes including toxin exposure, underlying neurological disease, infectious diseases, an unknown trauma should be considered in this case. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.